Technical Analysis for FOLD - Amicus Therapeutics, Inc.

Grade Last Price % Change Price Change
D 21.835 -6.25% -1.46
FOLD closed down 6.25 percent on Friday, January 15, 2021, on 71 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical FOLD trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Fell Below 50 DMA Bearish 0.00%
20 DMA Resistance Bearish -6.25%
Up 3 Days in a Row Strength -6.25%
50 DMA Support Bullish -4.98%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -4.98%
NR7 Range Contraction -4.98%
NR7-2 Range Contraction -4.98%
NR7 Range Contraction -4.36%
20 DMA Resistance Bearish -3.77%
Older End-of-Day Signals for FOLD ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Amicus Therapeutics, Inc. Description

Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs known as pharmacological chaperones. It develops pharmacological chaperones as next-generation medicines for a range of rare and orphan diseases with a focus on improved therapies for lysosomal storage disorders. The company's development programs include small molecules as monotherapy treatments for Fabry and other lysosomal storage diseases, and enzyme replacement therapy (ERT). Its chaperone-advanced replacement therapy programs comprise chaperones co-administered with currently marketed ERTs, as well as proprietary therapeutic enzymes co-formulated with pharmacological chaperones as next-generation ERTs. The company's primary product includes migalastat HCl, a product candidate for Fabry disease that is in Phase III global registration studies for patients with genetic mutations. Its products also comprise AT2220, which has completed Phase II safety used for the treatment of Pompe disease; and AT3375 and afegostat tartrate that are in preclinical studies used for treating Gaucher disease. The company has strategic collaboration with GlaxoSmithKline PLC to develop and commercialize migalastat HCl. Amicus Therapeutics, Inc. was founded in 2002 and is based in Cranbury, New Jersey.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Rare Diseases Enzymes Glaxosmithkline Orphan Disease Orphan Diseases Inborn Errors Of Metabolism Lipid Storage Disorders Enzyme Replacement Therapy Fabry Disease Gaucher Disease Lysosomal Storage Disorder Orphan Drugs Lysosomal Storage Disorders Pompe Disease Protein Folding Rare And Orphan Diseases

Is FOLD a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 25.39
52 Week Low 6.25
Average Volume 2,304,699
200-Day Moving Average 16.14
50-Day Moving Average 22.73
20-Day Moving Average 23.26
10-Day Moving Average 22.80
Average True Range 1.15
ADX 18.87
+DI 21.74
-DI 23.05
Chandelier Exit (Long, 3 ATRs ) 21.95
Chandelier Exit (Short, 3 ATRs ) 24.79
Upper Bollinger Band 24.90
Lower Bollinger Band 21.61
Percent B (%b) 0.07
BandWidth 14.14
MACD Line 0.03
MACD Signal Line 0.20
MACD Histogram -0.1709
Fundamentals Value
Market Cap 5.69 Billion
Num Shares 261 Million
EPS -2.13
Price-to-Earnings (P/E) Ratio -10.25
Price-to-Sales 24.35
Price-to-Book 18.91
PEG Ratio -0.18
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 24.18
Resistance 3 (R3) 24.43 23.90 23.79
Resistance 2 (R2) 23.90 23.30 23.77 23.66
Resistance 1 (R1) 22.87 22.93 22.60 22.62 23.53
Pivot Point 22.33 22.33 22.20 22.21 22.33
Support 1 (S1) 21.30 21.73 21.03 21.05 20.14
Support 2 (S2) 20.77 21.36 20.64 20.01
Support 3 (S3) 19.74 20.77 19.88
Support 4 (S4) 19.49